Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet): a survey of chronically infected individuals

被引:155
作者
Brindeiro, RM
Diaz, RS
Sabino, EC
Morgado, MG
Pires, IL
Brigido, L
Dantas, MC
Barreira, D
Teixeira, PR
Tanuri, A
机构
[1] Univ Fed Rio de Janeiro, Dept Genet, Mol Virol Lab, Ilha Fdn, BR-21944970 Rio De Janeiro, Brazil
[2] Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo Goes, BR-21944970 Rio De Janeiro, Brazil
[3] Fdn Inst Oswaldo Cruz, Dept Imunol, Rio De Janeiro, Brazil
[4] Inst Biol Exercito, Virol Lab, Rio De Janeiro, Brazil
[5] Univ Fed Sao Paulo, Paulista Sch Med, Lab Retrovirol, Sao Paulo, Brazil
[6] Univ Sao Paulo, Hemoctr Sao Paulo, Fdn Pro Sangue, Sao Paulo, Brazil
[7] Inst Adolfo Lutz Registro, Lab Retrovirol, Sao Paulo, Brazil
[8] Minist Hlth, CN DST AIDS, Brasilia, DF, Brazil
关键词
drug resistance; genotyping; HIV surveillance;
D O I
10.1097/00002030-200305020-00016
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To study the prevalence of HIV drug resistance mutations and subtype distribution in a Brazilian drug-naive population. Asymptomatic, drug-naive HIV-1-infected individuals were targeted in 13 voluntary counseling and testing centers spread around the country. Methods: Plasma viral RNA was extracted from 535 HIV-1-positive subjects. Protease (PR) and reverse transcriptase (RT) genomic regions were sequenced for subtype determination and analysis of drug resistance mutations. Results: Eight samples (2.24%) showed primary mutations related to protease inhibitor (PI) resistance, eight (2.36%) to nucleoside reverse transcriptase inhibitors (NRTI) and seven (2.06%) to non-nucleoside reverse transcriptase inhibitors (NNRTI). Accessory mutations were found in the PR gene at the following positions: L63P/V/T/A/I [153/345 (44.3%)], M36I/L [149/345 (43.2%)], L10I/F/V [82/345 (23.8%)], V771 [60/345 (17.4%)],A71V/T [11/345 (3.2%)], K20M/R [10/345 (2.9%)], and V821[4/345 (1.2%)]. Mutations known to be associated with reduced sensitivity to NRTI or NNRTI (V118I, E44D, K219R, T69A, and V75L) were found in a low prevalence (0.6-2.4%). A high proportion of the isolates from subtype C was found in the southern states. Subtype F-related viruses were the main non-B variant in the rest of the country. Conclusions: Brazil has a low prevalence of drug-resistant strains circulating among recently diagnosed individuals. However, there was an increase in these rates compared with similar studies performed with samples collected in Brazil from 1996 to 1998. Continued surveys are required to detect trends in these rates, but routine genotypic testing in the drug-naive population prior to antiretroviral initiation is not required in Brazil. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:1063 / 1069
页数:7
相关论文
共 62 条
  • [1] Analysis of HIV type 1 protease and reverse transcriptase in antiretroviral drug-naive Ugandan adults
    Becker-Pergola, G
    Kataaha, P
    Johnston-Dow, L
    Fung, S
    Jackson, JB
    Eshleman, SH
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (08) : 807 - 813
  • [2] HIV-1 drug resistance in newly infected individuals
    Boden, D
    Hurley, A
    Zhang, LQ
    Cao, YZ
    Guo, Y
    Jones, E
    Tsay, J
    Ip, J
    Farthing, C
    Limoli, K
    Parkin, N
    Markowitz, M
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (12): : 1135 - 1141
  • [3] Bongertz V, 2000, J ACQ IMMUN DEF SYND, V23, P184
  • [4] Resistance to antiretroviral drugs in patients with primary HIV-1 infection
    Brenner, B
    Wainberg, MA
    Salomon, H
    Rouleau, D
    Dascal, A
    Spira, B
    Sekaly, RP
    Conway, B
    Routy, JP
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2000, 16 (04) : 429 - 434
  • [5] Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid
    Briones, C
    Pérez-Olmeda, M
    Rodríguez, C
    del Romero, J
    Hertogs, K
    Soriano, V
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2001, 26 (02) : 145 - 150
  • [6] Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion
    Brodine, SK
    Shaffer, RA
    Starkey, MJ
    Tasker, SA
    Gilcrest, JL
    Louder, MK
    Barile, A
    VanCott, TC
    Vahey, MT
    McCutchan, FE
    Birx, DL
    Richman, DD
    Mascola, JR
    [J]. ANNALS OF INTERNAL MEDICINE, 1999, 131 (07) : 502 - +
  • [7] Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART
    Caride, E
    Brindeiro, R
    Hertogs, K
    Larder, B
    Dehertogh, P
    Machado, E
    de Sá, CAM
    Eyer-Silva, WA
    Sion, FS
    Passioni, LFC
    Menezes, JA
    Calazans, AR
    Tanuri, A
    [J]. VIROLOGY, 2000, 275 (01) : 107 - 115
  • [8] Antiretroviral therapy for HIV infection in 1998 - Updated recommendations of the International AIDS Society USA panel
    Carpenter, CCJ
    Fischl, MA
    Hammer, SM
    Hirsch, MS
    Jacobsen, DM
    Katzenstein, DA
    Montaner, JSG
    Richman, DD
    Saag, MS
    Schooley, RT
    Thompson, MA
    Vella, S
    Yeni, PG
    Volberding, PA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (01): : 78 - 86
  • [9] Césaire R, 1999, J ACQ IMMUN DEF SYND, V22, P401
  • [10] CHAIX ML, 2001, 8 C RETR OPP INF CHI